Your browser doesn't support javascript.
Development of a deep learning-based quantitative structure-activity relationship model to identify potential inhibitors against the 3C-like protease of SARS-CoV-2.
Kumari, Madhulata; Subbarao, Naidu.
  • Kumari M; Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, 303002, India.
  • Subbarao N; School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India.
Future Med Chem ; 14(21): 1541-1559, 2022 11.
Article in English | MEDLINE | ID: covidwho-2055773
ABSTRACT

Background:

In the recent COVID-19 pandemic, SARS-CoV-2 infection spread worldwide. The 3C-like protease (3CLpro) is a promising drug target for SARS-CoV-2.

Results:

We constructed a deep learning-based convolutional neural network-quantitative structure-activity relationship (CNN-QSAR) model and deployed it on various databases to predict the biological activity of 3CLpro inhibitors. Subsequently, molecular docking analysis, molecular dynamics simulations and binding free energy calculations were performed to validate the predicted inhibitory activity against 3CLpro of SARS-CoV-2. The model showed mean squared error = 0.114, mean absolute error = 0.24 and predicted R2 = 0.84 for the test dataset. Diosmin showed good binding affinity and stability over the course of the simulations.

Conclusion:

The results suggest that the proposed CNN-QSAR model can be an efficient method for hit prediction and a new way to identify hit compounds against 3CLpro of SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Deep Learning / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Future Med Chem Year: 2022 Document Type: Article Affiliation country: Fmc-2021-0063

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Deep Learning / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Future Med Chem Year: 2022 Document Type: Article Affiliation country: Fmc-2021-0063